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Decoding health and disease pathways drives healthcare evolution. Historically, therapeutic 
paradigms have relied on interventions that mitigate symptoms of established diseases. 
Increasingly, molecular insights into pathophysiology now provide unprecedented 
opportunities to offer curative solutions or even prevent disease and thereby secure 
longitudinal wellness. These opportunities extend past individual patients to entire 
populations and geographies. Moreover, they optimize prospective healthspan across 
lifespan. Linking discovery science and its translatable innovations beyond reactive disease 
intervention to proactive prevention will maximize society’s returns creating the greatest 
benefit for the greatest number of people globally. 
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Innovation distinguishes between a leader and a follower. 
Steve Jobs 
Biological discovery, associated with advances in enabling technologies, have transformed 
healthcare management paradigms for patients and populations.1 This transformation reflects 
logarithmic expansion of our molecular, technological and engineering enterprises, driven by 
investments from the public and private sectors.2 Evolution in discovery and technology impels 
the emergence of precision healthcare solutions, extending insights in biological systems to the 
pathophysiology underlying disease, yielding mechanism-based targets for curative therapies.3 
In that context, the growing toolkit of enabling omic and informatics platforms has yielded 
extraordinary opportunities to customize curative therapies that can be deployed to 
individuals, communities, and global populations.4 Indeed, molecular and technological 
innovations have been translated by a burgeoning biopharmaceutical industry into new 
paradigms that interrupt the lifecycle of disease, whose reach and impact are amplified by 
international regulatory agencies that ensure safe access to global populations.5 Moreover, 
clinical paradigms emerging from these molecularly-directed therapies shifts the “average 
patient” model of healthcare management to individualized solutions for disease 
interventions.6 These advancements are positioned to transform our concepts of health, 
revealed in developing fields like regenerative medicine, impelling the control of degenerative 
diseases by mobilizing inherent reserves that support rebuilding (tissue) health.7, 8 
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An ounce of prevention is worth a pound of cure. 
Benjamin Franklin 
This revolution in molecular insights into the pathophysiological underpinnings of disease has 
created an unprecedented opportunity to go beyond our reactionary approach to healthcare.9 
In that context, much of medicine today is based on the practice of intervening to interrupt the 
progression of established disease.10 Traditionally, therapeutic intervention is designed to treat 
the patient to correct the cause of the pathophysiology and alleviate the symptoms of, or even 
cure, disease.11 We are all familiar with the paradigms of treating infections with antimicrobials; 
intervening with chemotherapy in patients with cancer to improve disease-free and overall 
survival; and placing stents in blood vessels occluded with plaque to relieve the risks of 
coronary artery disease.11, 12 Over the past decades, the advantages of preventing disease, 
rather than intervening with therapy in established disease, have become manifest. In that 
context, it is more effective to prevent infections through vaccination; cancer by mitigating 
environmental exposures like smoking; and heart disease through diet, exercise, and metabolic 
management.13 Indeed, preventing disease, rather than interventions that interrupt the 
progression of established disease, is more effective from the perspective of providing the 
greatest health benefits to the greatest number of people.13 Moreover, prevention has proven 
to be one of the most cost-effective ways to achieve improved population health.13 To place 
that economic argument into context, three fourths of US health spending is directed at 
treating chronic disease, and two-thirds of the growth in health spending is attributable to 
worsening health habits of the American population.8, 12-14 This, in part, reflects a healthcare 
delivery system that places a priority on reimbursing for the treatment of chronic illness, rather 
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than preventing disease in the first place.13 In that context, advancing molecular and 
regenerative approaches, in conjunction with enabling informatics and omic technologies, offer 
unique opportunities to evolve preventive strategies that promote healthy aging and 
longitudinal wellness across the continuum from inception to senescence.1, 3, 5 
Beauty is only skin deep 
Sir Thomas Overbury 
These considerations of primary prevention are exemplified by considering skin and aging. Skin 
is equipped with an intricate network of antioxidants and antioxidant enzymes that oppose 
damage, induced by ultraviolet radiation and airborne pollutants which lead to accelerated 
photoaging, preneoplasias, and cancers. In that context, topical antioxidants, including vitamins 
C and E and selenium, create a reservoir that prevents, and reverses, environmental oxidative 
stress.15 Vitamin C is the body’s major aquaphase antioxidant, but must be provided 
exogenously because primates lack the appropriate synthetic enzymes. As an antioxidant, 
vitamin C deactivates UV- and pollution-induced free radicals, reactivates tumor suppressor 
genes to protect against UV-induced apoptosis, and directly opposes inflammation by 
deactivating nuclear factor kβ. Vitamin E is the most important lipid-soluble, membrane-bound 
antioxidant, brought to the stratum corneum by sebum. Vitamin E significantly reduces acute 
damaging effects to skin, including erythema, edema, sunburn cells, lipid peroxidation, DNA-
adduct formation, and inflammation. Selenium is an essential trace element required by 
selenoproteins which regulate antioxidant defenses, inflammation, thyroid and lipid 
metabolism, DNA synthesis, and immunity. Topical antioxidants not only photoprotect but also 
reverse environmental damage. Topical application of these agents reactivates senescent skin 
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fibroblasts, and inactivates UV-induced matrix metalloproteinases, to restore collagen and 
elastin production and accumulation opposing and reversing photo- and environmental-aging 
underlying wrinkles, preneoplasias, and skin cancers. Regular protection using these topical 
approaches has the potential to prevent injury, and maintain the youthfulness, of the largest 
surface area of the body.15 
Body building is the closest we have to the fountain of youth 
Lee Labrada 
Increases in average life expectancy, in part, reflecting reductions in childhood mortality, the 
development of antibiotics, and, more recently, advances in the treatment of chronic diseases 
have produced greater numbers of individuals living to adulthood.16 In turn, increases in 
longevity result in more older adults experiencing age-related senescence across multiple 
physiological systems. Geriatric syndromes, including sarcopenia, or muscle loss, and frailty, 
reflect declines in physiological function that occur over decades. These conditions have 
become more clinically relevant, reflecting a greater percentage of our total healthcare 
expenditure, as the population ages. The goal of preventative efforts in this domain is to 
improve mobility, strength, functional independence and quality of life to promote healthy 
aging and the maintenance of longitudinal wellness in older adults. Indeed, for these 
individuals, the focus is directed at increasing the number of years of life without disability. 
While, historically, geriatric medicine has typically been delivered through maintenance 
approaches, including clinical care, physical rehabilitation, and nutritional support, recent 
advances in the biology of aging and senescence have revealed opportunities for new 
preventive interventions.16 These recent innovations raise the possibility of not only 
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attenuating the negative effects of aging, but in many cases reversing those effects.16, 17 Indeed, 
these insights have led to the development of molecular interventions opposing the frailty and 
the loss of functional muscle mass associated with growing old that promise to extend healthy 
aging and create a virtual fountain of youth.16 
At the other extreme of the developmental continuum, novel approaches in regenerative 
medicine are being applied in utero to address severe congenital conditions at the prenatal 
stage, offering a unique opportunity for the earliest forms of disease prevention and 
prophylaxis.18 In that context, prenatal regenerative prophylaxis’ harnesses the plasticity of 
developing fetal organs to deliver postnatal pediatric health. Here, fetal surgery, implemented 
to reconstitute early normal organ growth and restore function in select congenital conditions, 
is increasingly considered to improve postnatal outcomes. Thus, congenital diaphragmatic 
hernia (CDH) is characterized by a diaphragmatic defect during fetal development that allows 
abdominal cavity contents to herniate through, and ultimately interfere with, lung 
development. CDH affects 1 in 3,836 births, and is associated with a high morbidity and 
mortality due to severe pulmonary hypoplasia and pulmonary arterial hypertension. IN that 
regard, fetal endoscopic tracheal occlusion has been performed for isolated severe CDH to 
promote fetal lung re-growth and restitution of organ development.18 Further, spina bifida is a 
congenital defect of the neural tube defined by the exposure of meninges and spinal cord due 
to incomplete closure of the spinal canal. Exposure of the neural tube to amniotic fluid and 
trauma in utero increase the risk of paralysis, abnormal mental development, and bladder 
and/or bowel dysfunction. Advances in ultrasound technology allow diagnosis of this condition 
as early as the first trimester. Accordingly, in utero surgical repair approaches have been 
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developed and children who underwent this procedure had improved brain and motor 
function, and reduced risk of postnatal hydrocephalus, resulting in higher psychomotor 
development scores.18 These observations highlight the transformative potential of 
regenerative therapeutic care in utero to preventive postnatal disease and disability.19 
These considerations underscore the importance of maintaining a focus on preventive 
approaches that complement therapeutic interventions, as our mechanistic armamentarium 
evolves from discoveries of the biological bases of health and disease.2, 11, 20-22 While molecular 
innovation has been impressive, the translation of those discovery-based insights into 
preventive therapies for individual patients which are scalable to populations must remain a 
priority.1, 3, 5 Emerging clinical paradigms should maximize the impact of discovery innovations 
by facilitating their translation into novel preventive algorithms to maintain longitudinal health 
and wellness, at all points along the developmental continuum. Indeed, advances in the 
emerging science of disease prevention offer the greatest opportunities to favorably impact the 
largest number of people across global communities and populations.13 
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